多巴胺D_(3)受体选择性配体研究进展  

Research Progress on Selective Ligands of Dopamine D_(3) Receptor

作　　者：李扛 许军[1] 刘燕华[1] 张奥旋 孙超钰 李铭东 Li Kang;Xu Jun;Liu Yanhua;Zhang Aoxuan;Sun Chaoyu;Li Mingdong(Jiangxi University of Chinese Medicine,Nanchang 330004,China)

机构地区：[1]江西中医药大学,江西南昌330004

出　　处：《山东化工》2023年第3期107-113,共7页Shandong Chemical Industry

基　　金：2021年度江西省研究生创新专项资金(YC2021-S507)。

摘　　要：近年来多巴胺D3受体(DRD_(3))在神经系统疾病的治疗过程中受到大量关注,包括帕金森、精神分裂、药物依赖等。本文综述2015年至今多巴胺D3受体选择性配体的研究进展,并以分子动力学原理为基础,利用Discovery Studio 4.5软件评价了这些配体的选择性,建立了基于分子共同特征的药效团模型,从类药分子库中筛选出对设计新型配体具有先导化合物意义的小分子化合物,以期对D3受体选择性配体的研究提供参考。In recent years,dopamine D_(3) receptor(DRD_(3))has attracted a lot of attention in the treatment of nervous system diseases,including Parkinson's disease,schizophrenia,drug abuse and so on.In this paper,the research progress of dopamine D_(3) receptor selective ligands from 2015 to now is reviewed.Based on the principle of molecular dynamics,the selectivity of these ligands is evaluated by Discovery Studio 4.5,a pharmacophore model based on the common characteristics of molecules is established,and small molecular compounds of significance for the design of new ligands are screened from the drug like molecular library,in order to provide reference for the study of D_(3) receptor selective ligands.

关 键 词：多巴胺D_(3)受体 选择性配体 神经系统疾病 计算机辅助药物设计 药效团模型 

分 类 号：TQ463[化学工程—制药化工] R971[医药卫生—药品]